Randomised double blind controlled trial of cyclosporin in multiple sclerosis.
In a 2 year double blind controlled trial of cyclosporin against placebo in multiple sclerosis conducted at two centres there was a beneficial effect of the therapy upon the progression of the disease, relapse rate and relapse severity at one of the centres where the patients received a mean dose of 7.2 mg/kg/day. This beneficial effect was not seen in the other centre where a lower dose (mean 5 mg/kg/day) was given. Reduction in clinical progression was accompanied by decreased IgG synthesis in the central nervous system. Side effects included hypertension, renal insufficiency and anaemia and were of such severity to preclude the use of cyclosporin in a high enough dose to alter the course of the disease.
Rudge
P
P
National Hospital for Nervous Diseases, London, UK.
Koetsier
J C
JC
Mertin
J
J
Mispelblom Beyer
J O
JO
Van Walbeek
H K
HK
Clifford Jones
R
R
Harrison
J
J
Robinson
K
K
Mellein
B
B
Poole
T
T
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008131:London; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009426:Netherlands; D011897:Random Allocation; D015375:Receptors, Interleukin-2 / Q000032:analysis
D003524:Cyclosporins; D015375:Receptors, Interleukin-2